{"url":"https://newsforagent.com/news/2026-10-20/basilea-idweek-2026-data-presentations","markdown_url":"https://newsforagent.com/news/2026-10-20/basilea-idweek-2026-data-presentations.md","title":"Basilea Pharmaceutica Presents New Anti-Infective Data at IDWeek 2026","headline":"Basilea Pharmaceutica to Present New Data on Fosmanogepix, Isavuconazole and Ceftobiprole at IDWeek 2026","description":"Basilea Pharmaceutica will present new data on fosmanogepix, isavuconazole and ceftobiprole at IDWeek 2026, including pediatric expanded access results.","section":"Research & Clinical Trials","published_at":"2026-10-20T05:47:03+00:00","modified_at":"2026-10-20T05:47:03+00:00","author":"News Desk","key_takeaways":["Basilea Pharmaceutica announced new data presentations for fosmanogepix, isavuconazole and ceftobiprole at IDWeek 2026 in Washington D.C. from October 21 to 24.","The fosmanogepix presentations include pediatric data from an Expanded Access Program and activity of its active moiety, manogepix, against Candida auris isolates.","Basilea's partner Asahi Kasei Therapeutics started a Phase-2 study of Cresemba (isavuconazole) in children in Japan in September 2026."],"companies":[{"name":"Basilea Pharmaceutica","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0000h3u/basilea-pharmaceutica","website":"http://basilea.com"}],"source":{"publisher":"FinancialContent Business Page","title":"Basilea reports presentation of new data for fosmanogepix, isavuconazole and ceftobiprole at IDWeek 2026","url":"https://www.financialcontent.com/article/gnwcq-2026-10-20-basilea-reports-presentation-of-new-data-for-fosmanogepix-isavuconazole-and-ceftobiprole-at-idweek-2026"},"other_sources":[],"tags":["Research & Clinical Trials","Basilea Pharmaceutica"],"body_markdown":"[Basilea Pharmaceutica](https://akta.pro/company-profiles/0000h3u/basilea-pharmaceutica) Ltd, Allschwil announced that new data on its phase 3 antifungal fosmanogepix, the antifungal isavuconazole (Cresemba) and the antibiotic ceftobiprole (Zevtera) will be presented at IDWeek 2026, held from October 21 to 24 in Washington D.C. The [FinancialContent Business Page](https://www.financialcontent.com/article/gnwcq-2026-10-20-basilea-reports-presentation-of-new-data-for-fosmanogepix-isavuconazole-and-ceftobiprole-at-idweek-2026) reported the announcement on October 20, 2026.\n\n## Fosmanogepix Pediatric and Candida auris Data at IDWeek\n\nBasilea said the presentations include oral presentations of pediatric data from the fosmanogepix Expanded Access Program and the activity of its active moiety, manogepix, against Candida auris isolates. The pediatric presentation, titled \"Fosmanogepix Expanded Access Experience in Pediatric Patients ≤11 Years of Age with Invasive Mold Infections,\" is scheduled for October 23, 2026, from 10:42 to 10:54 am, with L. E. Hastings as presenting author. A presentation on manogepix activity against Candida auris isolates from the United States is set for October 23, 2026, from 4:15 to 4:30 pm, with M. Winkler as presenting author. Three posters on manogepix activity against Aspergillus spp. isolates with CYP51 alterations, mold isolates across geographic regions, and yeast and mold isolates from 2025 in the United States are scheduled for October 22, 2026, from 12:15 to 1:30 pm, all with M. Winkler as presenting author.\n\nDr. Marc Engelhardt, Chief Medical Officer of Basilea, said: \"The breadth of data being presented at IDWeek across Basilea's anti-infectives portfolio by us, our partners, collaborators and independent research groups, underscores the strong scientific interest in advancing the treatment of serious fungal and bacterial infections.\"\n\n## Isavuconazole and Ceftobiprole Presentations\n\nIsavuconazole data at IDWeek 2026 include a rapid-fire poster session on isavuconazole versus alternative azoles for invasive Aspergillus in solid organ transplant recipients, scheduled for October 23, 2026, from 12:30 to 12:35 pm, with M. A. Colaluca, K. Marsh, Y. Li, C. Otto and M. Ringer as rapid fire presenters. A poster on hepatotoxicity signals across azole antifungals using the FDA Adverse Event Reporting System is set for October 22, 2026, from 12:15 to 1:30 pm, with V. Thiruvadi as presenting author. A poster on adoption of isavuconazole in pediatrics, a multi-center survey, is scheduled for October 22, 2026, from 12:15 to 1:30 pm, with C. Lan as presenting author.\n\nCeftobiprole data include a poster on pediatric dose selection for Staphylococcus aureus bacteremia, including right-sided infective endocarditis using model-based approaches, scheduled for October 22, 2026, from 12:15 to 1:30 pm, with A. Tanudra as presenting author. A poster on in vitro activity of ceftobiprole and comparator agents against contemporary US clinical isolates collected in 2025 following FDA approval is set for October 22, 2026, from 12:15 to 1:30 pm, with R. E. Mendes as presenting author. A poster on extrapolation of adult efficacy and safety to support pediatric use of ceftobiprole for acute bacterial skin and skin structure infections is scheduled for October 24, 2026, from 12:15 to 1:30 pm, with K. B. Larson as presenting author.\n\n## Basilea's Recent Pipeline and Partnership Moves\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Basilea initiated a first-in-human Phase 1 clinical study of novel antibiotic BAL2420 (LptA inhibitor) in Allschwil in March 2026. The same records show Basilea partnered with Phare Bio in December 2025 to apply AI-driven molecule design to novel antibiotic discovery. In January 2026, Basilea joined INCATE as an industry partner, one of four alongside Roche, Shionogi and MSD, and partnered with Prokaryotics Inc. to jointly develop a first-in-class broad-spectrum antifungal for severe invasive infections caused by Candida, Aspergillus and rare molds.\n\n## Earlier Basilea Developments\n\nIn September 2026, Basilea's partner Asahi Kasei Therapeutics started a Phase-2 study of Cresemba (isavuconazole) in children at risk for deep fungal infections in Japan, FinanzNachrichten.de reported. In August 2026, Basilea reported a 14% increase in first-half revenue to CHF 119 million and doubled its full-year operating profit guidance to approximately 40% growth, driven by strong sales of Cresemba and rising royalty income, Investing.com reported. Basilea also reported H1 2026 earnings of CHF 2.13 per share and raised full-year guidance, driven by a 14% increase in royalty income from its partnership with Merck KGaA for Cresemba, AInvest reported.\n\n## Next Steps for Basilea Pharmaceutica\n\nIDWeek 2026 takes place from October 21 to 24 in Washington D.C. The fosmanogepix pediatric presentation is scheduled for October 23, 2026, from 10:42 to 10:54 am, and the manogepix Candida auris presentation is set for October 23, 2026, from 4:15 to 4:30 pm.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}